Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins

[1]  Donald S. Grant,et al.  Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever , 2017, Nature Medicine.

[2]  H. Feldmann,et al.  Immunobiology of Ebola and Lassa virus infections , 2017, Nature Reviews Immunology.

[3]  Elizabeth M. Ryan,et al.  Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus , 2015, Cell.

[4]  Jens H. Kuhn,et al.  Past, present, and future of arenavirus taxonomy , 2015, Archives of Virology.

[5]  A. Peterson,et al.  Mapping Transmission Risk of Lassa Fever in West Africa: The Importance of Quality Control, Sampling Bias, and Error Weighting , 2014, PloS one.

[6]  P. Pushko,et al.  Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention , 2014 .

[7]  H. Feldmann,et al.  Vaccines for viral hemorrhagic fevers--progress and shortcomings. , 2013, Current opinion in virology.

[8]  I. Lukashevich.  The search for animal models for Lassa fever vaccine development , 2013, Expert review of vaccines.

[9]  Hollis G. Potter,et al.  Author Manuscript , 2013 .

[10]  I. Lukashevich,et al.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers. , 2012, Journal of vaccines & vaccination.

[11]  I. Lukashevich.  Advanced Vaccine Candidates for Lassa Fever , 2012, Viruses.

[12]  S. Kunz,et al.  Envelope Glycoprotein of Arenaviruses , 2012, Viruses.

[13]  H. Feldmann,et al.  Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity , 2012, Zoonoses and public health.

[14]  M. van den Broek,et al.  Stable Antigen Is Most Effective for Eliciting CD8+ T-Cell Responses after DNA Vaccination and Infection with Recombinant Vaccinia Virus In Vivo , 2012, Journal of Virology.

[15]  I. Lukashevich,et al.  Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. , 2012, Vaccine.

[16]  I. Lukashevich,et al.  Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. , 2011, Vaccine.

[17]  F. Urano,et al.  Measuring ER stress and the unfolded protein response using mammalian tissue culture system. , 2011, Methods in enzymology.

[18]  R. Hegde,et al.  Quality and quantity control at the endoplasmic reticulum. , 2010, Current opinion in cell biology.

[19]  D. Rogers,et al.  Risk Maps of Lassa Fever in West Africa , 2009, PLoS neglected tropical diseases.

[20]  R. Johnston,et al.  Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. , 2008, Vaccine.

[21]  S. Günther,et al.  Strain-specific antibody response to Lassa virus in the local population of west Africa. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[22]  J. Weber,et al.  A lymphocytic choriomeningitis virus glycoprotein variant that is retained in the endoplasmic reticulum efficiently cross-primes CD8+ T cell responses , 2007, Proceedings of the National Academy of Sciences.

[23]  I. Lukashevich,et al.  A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. , 2007, Vaccine.

[24]  Igor S. Lukashevich and Maria S. Salvato.  Lassa Virus Genome , 2006 .

[25]  V. Deubel,et al.  A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. , 2006, Virology.

[26]  I. Lukashevich,et al.  A Live Attenuated Vaccine for Lassa Fever Made by Reassortment of Lassa and Mopeia Viruses , 2005, Journal of Virology.

[27]  B. Mothé,et al.  Development of a New Vaccine for the Prevention of Lassa Fever , 2005, PLoS medicine.

[28]  I. Lukashevich,et al.  Ribonucleic acids of Machupo and Lassa viruses , 2005, Archives of Virology.

[29]  D. Tscharke,et al.  CD8+ T Cell Cross-Priming via Transfer of Proteasome Substrates , 2004, Science.

[30]  J. McCormick,et al.  Lassa fever vaccine , 2004, Expert review of vaccines.

[31]  A. Hoerauf,et al.  Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. , 2004, Virology.

[32]  J. Wilschut,et al.  Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. , 2004, Vaccine.

[33]  Debbie Baglole,et al.  Lassa fever: epidemiology, clinical features, and social consequences , 2003, BMJ : British Medical Journal.

[34]  P. Jahrling,et al.  Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs against Infection with Lassa and Ebola Viruses , 2001, Journal of Virology.

[35]  Stuart T. Nichol,et al.  Genetic Diversity among Lassa Virus Strains , 2000, Journal of Virology.

[36]  A. Hoerauf,et al.  Characterization of Human CD4+ T-Cell Clones Recognizing Conserved and Variable Epitopes of the Lassa Virus Nucleoprotein , 2000, Journal of Virology.

[37]  R. Johnston,et al.  Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. , 1997, Virology.

[38]  C. Peters,et al.  Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. , 1996, Vaccine.

[39]  I. Lukashevich,et al.  Lassa virus activity in Guinea: Distribution of human antiviral antibody defined using enzyme‐linked immunosorbent assay with recombinant antigen , 1993, Journal of medical virology.

[40]  D. Ron,et al.  CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. , 1992, Genes & development.

[41]  A. Anusz.  [Lassa fever]. , 1981, Pielegniarka i polozna.